ABBV 8-K 2026-10-05
AbbVie Inc. (ABBV) 8-K dated 2026-10-05 — accession 0001551152-26-000030.
AbbVie Inc. (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
ABBV: SECURITIES AND EXCHANGE COMMISSION
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 8.6% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 49.3.
Not investment advice. The ABBV SEC hub lists recent forms. The stock page is the research view.
- Guidance
- guidance for 2026 previously announced on July 31, 2026 excluded the impact of acquired IPR&D and milestones expense that may be
Why it matters
- guidance for 2026 previously announced on July 31, 2026 excluded the impact of acquired IPR&D and milestones expense that may be